Get the Stockscreener App
0.0237
0.86%
-0.0228
After Hours:
.02
-0.0037
-15.61%
Galera Therapeutics Inc stock is traded at $0.0237, with a volume of 46,626.
It is down -0.86% in the last 24 hours and down -43.95% over the past month.
See More
Previous Close:
$0.0465
Open:
$0.0258
24h Volume:
46,626
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-69.68M
P/E Ratio:
-0.0125
EPS:
-1.89
Net Cash Flow:
$-48.93M
1W Performance:
-0.86%
1M Performance:
-43.95%
6M Performance:
-23.49%
1Y Performance:
-96.95%
1-Day Range:
$0.0237
$0.0258
1-Week Range:
$0.0237
$0.0258
52-Week Range:
$0.0237
$0.0258
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare GRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0237 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com Australia
Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com
Galera Therapeutics holds annual stockholder meeting By Investing.com - Investing.com South Africa
Galera Therapeutics holds annual stockholder meeting - Investing.com India
Oral Mucositis Market to Expand Significantly by 2034, States DelveInsight Report - EIN News
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MSN
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MyChesCo
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
Galera Therapeutics director Nancy Chang buys $499,978 in stock By Investing.com - Investing.com South Africa
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics director Nancy Chang buys $499,978 in stock - Investing.com
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics Completes Nova Pharmaceuticals Acquisition - citybiz
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition - TipRanks
Oncotelic Therapeutics Implements PDAOAI Platform - The Manila Times
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - The Bakersfield Californian
Galera Therapeutics Acquires Nova Pharma, Pivots to Breast Cancer Drug Development with $3M Investment - StockTitan
Galera Therapeutics, Inc. acquired Nova Pharmaceuticals, Inc. - Marketscreener.com
Guardian Capital Partners Acquires Team LINX to Drive Growth in Technology Infrastructure - MyChesCo
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MyChesCo
At galera.bet, we promote an agenda of integrity, compliance and - Oficjalny Portal Gminy Brzesko
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Galera stockholders reject liquidation plan - Investing.com
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MyChesCo
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Galera Therapeutics Inc Stock (GRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
1.24%
Cap:
|
Volume (24h):